The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

被引:304
作者
Garces, Sandra [1 ,2 ,3 ]
Demengeot, Jocelyne [2 ]
Benito-Garcia, Elizabeth [4 ]
机构
[1] Hosp Garcia de Orta, Dept Rheumatol, Almada, Portugal
[2] Gulbenkian Inst Sci, Lymphocyte Physiol Grp, P-2781901 Oeiras, Portugal
[3] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal
[4] BioEPI Clin & Translat Res Ctr, Dept Epidemiol, Oeiras, Portugal
关键词
Autoimmune Diseases; Anti-TNF; Methotrexate; ANTITUMOR NECROSIS FACTOR; RHEUMATOID-ARTHRITIS PATIENTS; ALPHA MONOCLONAL-ANTIBODY; LONG-TERM TREATMENT; CLINICAL-RESPONSE; ADALIMUMAB ANTIBODIES; CONCOMITANT METHOTREXATE; ANKYLOSING-SPONDYLITIS; EPISODIC TREATMENT; CROHNS-DISEASE;
D O I
10.1136/annrheumdis-2012-202220
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Immunogenicity of aTNFs is one of the mechanisms behind treatment failure. Objective To assess the effect of anti-drug antibodies (ADA) on drug response to infliximab, adalimumab and etanercept, and the effect of immunosuppression on ADA detection, in patients with Rheumatoid Arthritis, Spondyloarthritis, Psoriasis and Inflammatory Bowel Diseases. Data sources PubMed, EMBASE, Cochrane databases, article reference lists (through August 19 2012). Study selection Out of 2082 studies, 17 were used in the meta-analysis (1RCT; 16 observational studies). Data extraction Two reviewers extracted data. Risk ratios (RR), 95% CI, using random-effect models, sensitivity analysis, meta-regressions and Egger's test were calculated. Data synthesis Of 865 patients, ADA against infliximab or adalimumab reduced drug response rate by 68% (RR=0.68, 95% CI=0.12 to 0.36), an effect attenuated by concomitant methotrexate (MTX): <74% MTX+: RR=0.23, 95% CI=0.15 to 0.36; 74% MTX+: RR=0.32, 95% CI=0.22 to 0.48. Anti-etanercept antibodies were not detected. Of 936 patients, concomitant MTX or azathioprine/mercaptopurine reduced ADA frequency by 47% (RR=0.53, 95% CI=0.42 to 0.67), particularly when ADA were assessed by RIA (RR=0.36, 95% CI=0.23 to 0.55) compared with ELISA (RR=0.63, 95% CI=0.53 to 0.74). Conclusions ADA reduces drug response, an effect that can be attenuated by concomitant immunosuppression, which reduces ADA frequency. Drug immunogenicity should be considered for the management of patients receiving biological therapies.
引用
收藏
页码:1947 / 1955
页数:9
相关论文
共 63 条
[31]   Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange [J].
Kolfschoten, Marijn van der Neut ;
Schuurman, Janine ;
Losen, Mario ;
Bleeker, Wim K. ;
Martinez-Martinez, Pilar ;
Vermeulen, Ellen ;
den Bleker, Tamara H. ;
Wiegman, Luus ;
Vink, Tom ;
Aarden, Lucien A. ;
De Baets, Marc H. ;
van De Winkel, Jan G. J. ;
Aalberse, Rob C. ;
Parren, Paul W. H. I. .
SCIENCE, 2007, 317 (5844) :1554-1557
[32]   Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Antiadalimumab Antibodies [J].
Korswagen, L. A. ;
Bartelds, G. M. ;
Krieckaert, C. L. M. ;
Turkstra, F. ;
Nurmohamed, M. T. ;
van Schaardenburg, D. ;
Wijbrandts, C. A. ;
Tak, P. P. ;
Lems, W. F. ;
Dijkmans, B. A. C. ;
van Vugt, R. M. ;
Wolbink, G. J. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (04) :877-883
[33]   Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner [J].
Krieckaert, Charlotte L. ;
Nurmohamed, Michael T. ;
Wolbink, Gerrit Jan .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) :1914-1915
[34]  
Lecluse LLA, 2010, ARCH DERMATOL, V146, P127, DOI 10.1001/archdermatol.2009.347
[35]  
Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
[36]   IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab [J].
Magdelaine-Beuzelin, Charlotte ;
Vermeire, Severine ;
Goodall, Margaret ;
Baert, Filip ;
Noman, Maja ;
Van Assche, Geit ;
Ohresser, Marc ;
Degenne, Danielle ;
Dugoujon, Jean-Michel ;
Jefferis, Roy ;
Rutgeerts, Paul ;
Lefranc, Maire-Paule ;
Watier, Herve .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (05) :383-387
[37]   Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].
Maini, R ;
St Clair, EW ;
Breedveld, F ;
Furst, D ;
Kalden, J ;
Weisman, M ;
Smolen, J ;
Emery, P ;
Harriman, G ;
Feldmann, M ;
Lipsky, P .
LANCET, 1999, 354 (9194) :1932-1939
[38]  
Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO
[39]  
2-W
[40]   Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial [J].
Moreland, LW ;
Schiff, MH ;
Baumgartner, SW ;
Tindall, EA ;
Fleischmann, RM ;
Bulpitt, KJ ;
Weaver, AL ;
Keystone, EC ;
Furst, DE ;
Mease, PJ ;
Ruderman, EM ;
Horwitz, DA ;
Arkfeld, DG ;
Garrison, L ;
Burge, DJ ;
Blosch, CM ;
Lange, MLM ;
McDonnell, ND ;
Weinblatt, ME .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :478-+